Log in

Relevant bibliographies by topics / Hematological malignancie

Contents

Journal articles

Academic literature on the topic 'Hematological malignancie'

Author: Grafiati

Published: 14 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hematological malignancie.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hematological malignancie"

1

Miao, Miao, Wu Depei, Aining Sun, Ying Wang, Lingzhi Yan, and Qian Wu. "The Efficacy and Safety of Recombinant Human Thrombopoietin in Patients with Hematological Malgnancies After Allogeneic Hematopoietic Stem Cell Transplantation." Blood 118, no. 21 (2011): 4565. http://dx.doi.org/10.1182/blood.v118.21.4565.4565.

Full text

Abstract:

Abstract Abstract 4565 OBJECTIVE: To evaluate the efficacy and sefety of recombinant human thrombopoietin(rhTPO) prior to engraftment in adults with hematological malignancie who received allogeneic haematopoietil stem cell transplantation(Allo-HSCT). METHODS: This sutdy was a randomized, controlled clinical trial,38 patients were hematological malignancie, inclulding acute and chrinic myeloid leukemia, acute lymphoblastic leukemia, lymphoma.They received Allo-HSCT and were randomly divided into groups(group A 19 cases, group B 19 cases).The group A was no-rhTPO as control, the group B were re

APA, Harvard, Vancouver, ISO, and other styles

2

Dong, L., X.-Y. Zhai, Y.-L. Yang, et al. "P110 Population pharmacokinetics and dosing optimisation of imipenem in children with haematological malignancie." Archives of Disease in Childhood 104, no. 6 (2019): e63.3-e63. http://dx.doi.org/10.1136/archdischild-2019-esdppp.148.

Full text

Abstract:

BackgroundImipenem/cilastatin is widely used for the treatment of children with serious infections. Currently, there is lack of pharmacokinetic studies of imipenem in children with hematological malignancies. Given the significant impact of disease on pharmacokinetics and increased resistance, we aimed to conduct a population based pharmacokinetic study of imipenem and optimize the dosage regimens for this vulnerable population.MethodsAfter treated with IMP/CS, blood samples of children were collected and the concentration of imipenem were quantified using HPLC-UV. Then, population level pharm

APA, Harvard, Vancouver, ISO, and other styles

3

Zinzani, Pier Luigi, Enrico Derenzini, Cinzia Pellegrini, et al. "Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial." Blood 118, no. 21 (2011): 1604. http://dx.doi.org/10.1182/blood.v118.21.1604.1604.

Full text

Abstract:

Abstract Abstract 1604 We previously reported the results of a multicenter non-randomized phase II trial of fludarabine and mitoxantrone plus radioimmunotherapy (RIT) [FLUMIZ (Fludarabine, Mitoxantrone, Zevalin) trial], demonstrating that this combination was safe and very effective in untreated patients with follicular non-Hodgkin lymphoma. We are now providing long term efficacy and toxicity results of this combination strategy. Sixty-one patients with stage III and IV untreated follicular lymphoma were enrolled between June 2004 and April 2006, at 13 Italian institutions. Briefly, treatment

APA, Harvard, Vancouver, ISO, and other styles

4

Clemmensen, Signe B., Jennifer R. Harris, Jonas Mengel-From, et al. "Familial Risk and Heritability of Hematologic Malignancies in the Nordic Twin Study of Cancer." Cancers 13, no. 12 (2021): 3023. http://dx.doi.org/10.3390/cancers13123023.

Full text

Abstract:

We aimed to explore the genetic and environmental contributions to variation in the risk of hematologic malignancies and characterize familial dependence within and across hematologic malignancies. The study base included 316,397 individual twins from the Nordic Twin Study of Cancer with a median of 41 years of follow-up: 88,618 (28%) of the twins were monozygotic, and 3459 hematologic malignancies were reported. We estimated the cumulative incidence by age, familial risk, and genetic and environmental variance components of hematologic malignancies accounting for competing risk of death. The

APA, Harvard, Vancouver, ISO, and other styles

5

Asare, Mariette, Jeanne E. Hendrickson, and Christopher A. Tormey. "Determination of Red Blood Cell Alloimmunization Rates in Transfused Patients with Hematologic and Oncologic Malignancies." Blood 128, no. 22 (2016): 1463. http://dx.doi.org/10.1182/blood.v128.22.1463.1463.

Full text

Abstract:

Abstract Introduction: Patients with hematological and oncological malignancies are among the most frequent recipients of chronic red blood cell (RBC) transfusion therapy. One of the risks associated with chronic RBC exposure is the development of blood group antibodies. However, there are few extensive studies of alloimmunization rates associated with hematological or oncological malignancies in adult patients despite the frequency with which they are transfused. As such, the aims of this study were: 1) to determine the alloimmunization rate associated with malignant conditions in general, 2)

APA, Harvard, Vancouver, ISO, and other styles

6

Liao, Yongkang, Shijun Xiong, Zaid Ur Rehman, et al. "The Research Advances of Aptamers in Hematologic Malignancies." Cancers 15, no. 1 (2023): 300. http://dx.doi.org/10.3390/cancers15010300.

Full text

Abstract:

Currently, research for hematological malignancies is very intensive, with many breakthroughs. Among them, aptamer-based targeted therapies could be counted. Aptamer is a targeting tool with many unique advantages (easy synthesis, low toxicity, easy modification, low immunogenicity, nano size, long stability, etc.), therefore many experts screened corresponding aptamers in various hematological malignancies for diagnosis and treatment. In this review, we try to summarize and provide the recent progress of aptamer research in the diagnosis and treatment of hematologic malignancies. Until now, 2

APA, Harvard, Vancouver, ISO, and other styles

7

Yang, Xiao-Jing, Ya-Ming Xi, and Zi-Jian Li. "Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy." BioMed Research International 2019 (March 28, 2019): 1–7. http://dx.doi.org/10.1155/2019/4860268.

Full text

Abstract:

Hematological malignancies including leukemia and lymphoma can severely impact human health. With the current therapies combined with chemotherapy, stem cell transplantation, radiotherapy, and immunotherapy, the prognosis of hematologic malignancies improved significantly. However, most hematological malignancies are still incurable. Therefore, research for novel treatment options was continuing with the natural product as one source. Icaritin is a compound extracted from a traditional Chinese herb,Epimedium Genus, and demonstrated an antitumor effect in various neoplasms including hematologic

APA, Harvard, Vancouver, ISO, and other styles

8

Ren, Anqi, Xiqin Tong, Na Xu, Tongcun Zhang, Fuling Zhou, and Haichuan Zhu. "CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities." Vaccines 11, no. 1 (2023): 165. http://dx.doi.org/10.3390/vaccines11010165.

Full text

Abstract:

T-cell acute lymphoblastic leukemia (T-ALL), a form of T-cell malignancy, is a typically aggressive hematological malignancy with high rates of disease relapse and a poor prognosis. Current guidelines do not recommend any specific treatments for these patients, and only allogeneic stem cell transplant, which is associated with potential risks and toxicities, is a curative therapy. Recent clinical trials showed that immunotherapies, including monoclonal antibodies, checkpoint inhibitors, and CAR T therapies, are successful in treating hematologic malignancies. CAR T cells, which specifically ta

APA, Harvard, Vancouver, ISO, and other styles

9

YAEGASHI, HIROSHI, TAKAHIRO NOHARA, KAZUYOSHI SHIGEHARA, et al. "Survival Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Retrospective Single-institutional Experience." Cancer Diagnosis & Prognosis 2, no. 3 (2022): 352–59. http://dx.doi.org/10.21873/cdp.10116.

Full text

Abstract:

Background/Aim: Primary mediastinal non-seminomatous germ cell tumors (PMNSGCTs) are occasionally complicated by a hematologic malignancy, as with somatic-type malignant tumors called germ cell tumors with somatic-type malignancy (GCTSTM) and are known to have a poor prognosis. Patients and Methods: Data obtained between September 1997 and February 2020 for patients with mediastinal germ cell tumor at our institution were retrospectively analyzed. Key outcome measures included survival rates and the clinical features of non-seminoma cases. Results: Of 16 patients, 9 had pure seminoma, and 7 ha

APA, Harvard, Vancouver, ISO, and other styles

10

Krishnan, Gayathri, and Anupam Pande. "985. Fusarium Infections in Patients with Hematological Malignancies." Open Forum Infectious Diseases 8, Supplement_1 (2021): S583—S584. http://dx.doi.org/10.1093/ofid/ofab466.1179.

Full text

Abstract:

Abstract Background Fusarium is a ubiquitous mold that can cause invasive and disseminated fusariosis in immunosuppressed patients, especially those with hematological malignancies. The risk factors associated with mortality of patients with Fusarium infections have not been adequately assessed in literature. In this study, we sought to explore the characteristics, clinical outcomes, and risk factors for mortality in Fusarium infections in patients with hematological malignancies. Methods This is a retrospective study of adult hematological malignancy patients admitted to surgical/medical ward

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!